Posted On: 01/04/2015 8:24:21 AM
Post# of 30066
NanoSomiX is a startup company developing a couple of AD diagnostic tests. Not sure if they are as close as Amarantus is to launching from a timing ("This Fall" - did it happen?) and funding POV. If anything, this may be an example of the type of diagnostic asset(s) acquisition Amarantus is looking to do.
Sep 10, 2014 - "Study results showed that the assay could correctly classify 96.4% of AD cases and could identify pre-symptomatic patients up to 10 years prior to diagnosis. Consisting of two phases, the study involved a total of 162 subjects, half of them Alzheimer’s disease patients and half of them controls."
" This fall , the company will begin providing the test to researchers and pharmaceutical companies who are studying treatments for AD."
http://www.marketwatch.com/story/nanosomix-an...2014-09-10
December 11, 2014 - "Researchers from the National Institute on Aging evaluated 174 patients with 100 percent accuracy using the new test as either Alzheimer’s disease or healthy. The California based company that created the test, NanoSomiX, said they plan to create a commercialized version of the test. The research was presented at the Society for Neuroscience conference in Washington in November."
“ We will need replication and validation , but I’m very optimistic this work will hold,” the study’s lead author Dimitrios Kapogiannis, MD, described to Bloomberg. “We were able to perfectly classify patients and controls.” - See more at: http://www.hcplive.com/articles/Blood-Sample-...swgBs.dpuf
http://www.hcplive.com/articles/Blood-Sample-...s-Disease-
Sep 10, 2014 - "Study results showed that the assay could correctly classify 96.4% of AD cases and could identify pre-symptomatic patients up to 10 years prior to diagnosis. Consisting of two phases, the study involved a total of 162 subjects, half of them Alzheimer’s disease patients and half of them controls."
" This fall , the company will begin providing the test to researchers and pharmaceutical companies who are studying treatments for AD."
http://www.marketwatch.com/story/nanosomix-an...2014-09-10
December 11, 2014 - "Researchers from the National Institute on Aging evaluated 174 patients with 100 percent accuracy using the new test as either Alzheimer’s disease or healthy. The California based company that created the test, NanoSomiX, said they plan to create a commercialized version of the test. The research was presented at the Society for Neuroscience conference in Washington in November."
“ We will need replication and validation , but I’m very optimistic this work will hold,” the study’s lead author Dimitrios Kapogiannis, MD, described to Bloomberg. “We were able to perfectly classify patients and controls.” - See more at: http://www.hcplive.com/articles/Blood-Sample-...swgBs.dpuf
http://www.hcplive.com/articles/Blood-Sample-...s-Disease-
(0)
(0)
